Cargando…
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
Microscaled proteogenomics was deployed to probe the molecular basis for differential response to neoadjuvant carboplatin and docetaxel combination chemotherapy for triple-negative breast cancer (TNBC). Proteomic analyses of pretreatment patient biopsies uniquely revealed metabolic pathways, includi...
Ejemplares similares
-
Microscaled proteogenomic methods for precision oncology
por: Satpathy, Shankha, et al.
Publicado: (2020) -
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy
por: Krug, Karsten, et al.
Publicado: (2020) -
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer
por: Gou, Xuxu, et al.
Publicado: (2021) -
Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases
por: Higashiyama, Nicole, et al.
Publicado: (2020) -
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins
por: Wang, Junkai, et al.
Publicado: (2023)